Several biomarkers have a higher level of validation such as PD-L1 expression on cancer cells and microsatellite instability (MSI); others, such as BRCA mutation status and tumor mutation burden (TMB) showed more often contradictory results [41]. This evidence concerns the gene CD274 and cancer.